 |
 |
|
 |
||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Funded Clinical Trial for Canine Multiple Myeloma
Antiangiogenic Treatment for Multiple Myeloma
An open-label study for dogs with multiple myeloma is now available. Dogs enrolled in this study are treated with an antiangiogenic peptide of Thrombospondin-1 (TSP-1). The rationale for this study follows an open-label evaluation of TSP-1 peptides for all cancers in which 4 of 4 dogs with soft tissue plasmacytomas had objective responses.
Clinical Trial for Canine Multiple Myeloma Patients
Trial eligibility criteria include:
- Measurable, histologically-confirmed multiple myeloma (based on the presence of hypergammaglobulinemia and bone marrow aspirate or bone biopsy)
- No previous exposure to antiangiogenic therapy
- No chemotherapy within 14 days of trial entry
- No radiation therapy administered within 21 days of trial entry
- Corticosteroids and NSAID’s acceptable if patient has been receiving them for >14 days at time of study entry
Trial support/funding includes:
- Pre-study abdominal/thoracic radiographs
- Initial bone marrow aspirate or biopsy
- Initial abdominal ultrasound
- Initial serum protein electrophoresis
- Recheck radiographs for the first 6 months of the study
- Recheck serum protein electrophoresis every 2 months for the first 6 months of the study
- Recheck globulin counts
- Bone marrow aspirate or biopsy at time of response and relapse
- Syringes for administration of the peptide
- The antiangiogenic peptide
*No additional funding will be provided after 6 months, but study drug will be available in a compassionate use setting if evidence of benefit.
Summary
Study patients must be evaluated for all study visits at a participating ACI network clinic. Eligible patients receive the investigational compound under closely monitored conditions while participating in the study. Dogs will be treated with twice daily subcutaneous injections and will receive follow-up, which includes monthly visits for tumor staging and bio-endpoint sample collection.
PO Box 42535
Washington, D.C. 20015
Email Us
